These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Chen S; Gomez SP; McCarley D; Mainwaring MG Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828 [TBL] [Abstract][Full Text] [Related]
25. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Whitacre CM; Zborowska E; Willson JK; Berger NA Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720 [TBL] [Abstract][Full Text] [Related]
26. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753 [TBL] [Abstract][Full Text] [Related]
27. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245 [TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerase inhibitors. Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607 [No Abstract] [Full Text] [Related]
29. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486 [TBL] [Abstract][Full Text] [Related]
30. DNA topoisomerase I poisons. Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479 [No Abstract] [Full Text] [Related]
31. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Godard T; Deslandes E; Sichel F; Poul JM; Gauduchon P Mutat Res; 2002 Sep; 520(1-2):47-56. PubMed ID: 12297143 [TBL] [Abstract][Full Text] [Related]
32. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485 [TBL] [Abstract][Full Text] [Related]
33. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802 [TBL] [Abstract][Full Text] [Related]
34. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Hartmann JT; Lipp HP Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321 [TBL] [Abstract][Full Text] [Related]
35. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624 [TBL] [Abstract][Full Text] [Related]
36. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166 [TBL] [Abstract][Full Text] [Related]
37. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439 [TBL] [Abstract][Full Text] [Related]
38. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P J Natl Cancer Inst; 2004 Oct; 96(19):1457-66. PubMed ID: 15467035 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367 [TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]